Looking for our Business Solutions? Click here:CloudQuote APIsContact Us
Home
Stocks in the NewsMost Active StocksPercent GainersPercent LosersFollowed Stocks
,

Latest News

FOX (NASDAQ:FOXA) Delivers Impressive Q1
Cable news and media network Fox (NASDAQ:FOXA) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 26.8% year on year to $4.37 billion. Its non-GAAP profit of $1.10 per share was 22.6% above analysts’ consensus estimates.
Via StockStory · May 12, 2025
Lincoln Educational (NASDAQ:LINC) Beats Q1 Sales Targets, Stock Soars
Education company Lincoln Educational (NASDAQ:LINC) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 13.7% year on year to $117.5 million. The company’s full-year revenue guidance of $490 million at the midpoint came in 1.2% above analysts’ estimates. Its GAAP profit of $0.06 per share was significantly above analysts’ consensus estimates.
Via StockStory · May 12, 2025
I'm Not Counting on Social Security COLAs to Carry Me Through Retirement. Here's What I'm Doing to Combat Inflation Instead.fool.com
Via The Motley Fool · May 12, 2025
Why I Own Joby Aviation Stockfool.com
Via The Motley Fool · May 12, 2025
Equity Futures Strongtalkmarkets.com
After massive rallies off the early-April lows, the major US equity indices are bumping against potentially crucial resistance.
Via Talk Markets · May 12, 2025
These High-Growth Stocks Were Down Over 50% This Year. Is It Time to Buy Them?fool.com
Via The Motley Fool · May 12, 2025
Chegg (NYSE:CHGG) Posts Better-Than-Expected Sales In Q1 But Quarterly Revenue Guidance Significantly Misses Expectations
Online study and academic help platform Chegg (NYSE:CHGG) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 30.4% year on year to $121.4 million. On the other hand, next quarter’s revenue guidance of $101 million was less impressive, coming in 9.2% below analysts’ estimates. Its non-GAAP loss of $0.06 per share was significantly below analysts’ consensus estimates.
Via StockStory · May 12, 2025
Surgery Partners (NASDAQ:SGRY) Posts Q1 Sales In Line With Estimates But Stock Drops
Healthcare company Surgery Partners (NASDAQ:SGRY) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 8.2% year on year to $776 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $3.38 billion at the midpoint. Its non-GAAP profit of $0.04 per share was $0.01 below analysts’ consensus estimates.
Via StockStory · May 12, 2025
Better Dividend Stock: Occidental Petroleum vs. Energy Transferfool.com
Which of these income-generating energy investments is a better buy right now?
Via The Motley Fool · May 12, 2025
Housing Downturn Accelerates In Apriltalkmarkets.com
Real estate is the most widely owned and leveraged asset, so housing downturns have historically led to the most painful economic contractions.
Via Talk Markets · May 12, 2025
ARISTA NETWORKS INC (NYSE:ANET) qualifies as a high growth stock and is consolidating.chartmill.com
Based on technical and fundamental analysis of NYSE:ANET we find: ARISTA NETWORKS INC (NYSE:ANET) qualifies as a high growth stock and is consolidating.
Via Chartmill · May 12, 2025
History Says Now Is the Time to Buy Nvidia Stockfool.com
Via The Motley Fool · May 12, 2025
Is BUNGE GLOBAL SA (NYSE:BG) a Good Fit for Dividend Investing?chartmill.com
Why the dividend investor may take a look at BUNGE GLOBAL SA (NYSE:BG).
Via Chartmill · May 12, 2025
Prediction: These 2 Stocks Will Outperform the Market in the Next Five Yearsfool.com
Via The Motley Fool · May 12, 2025
Monday.com (NASDAQ:MNDY) Beats Q1 Sales Targets, Stock Soars
Project management software maker Monday.com (NASDAQ:MNDY) announced better-than-expected revenue in Q1 CY2025, with sales up 30.1% year on year to $282.3 million. The company expects next quarter’s revenue to be around $293 million, close to analysts’ estimates. Its non-GAAP profit of $1.10 per share was 56.4% above analysts’ consensus estimates.
Via StockStory · May 12, 2025
GILD Q1 Earnings Call: HIV Growth and Pipeline Momentum Offset Revenue Miss
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance of $28.4 billion at the midpoint came in 1.1% below analysts’ estimates. Its non-GAAP profit of $1.81 per share was 2.1% above analysts’ consensus estimates.
Via StockStory · May 12, 2025
The Analyst Verdict: Ocugen In The Eyes Of 5 Expertsbenzinga.com
Via Benzinga · May 12, 2025
What 4 Analyst Ratings Have To Say About Silvaco Groupbenzinga.com
Via Benzinga · May 12, 2025
33 Analysts Have This To Say About Rokubenzinga.com
Via Benzinga · May 12, 2025
Sally Beauty (NYSE:SBH) Misses Q1 Sales Targets
Beauty supply retailer Sally Beauty (NYSE:SBH) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 2.8% year on year to $883.1 million. On the other hand, the company expects next quarter’s revenue to be around $942.3 million, close to analysts’ estimates. Its non-GAAP profit of $0.42 per share was 6.6% above analysts’ consensus estimates.
Via StockStory · May 12, 2025
Analyst Expectations For Insmed's Futurebenzinga.com
Via Benzinga · May 12, 2025
DraftKings Stock: A Deep Dive Into Analyst Perspectives (28 Ratings)benzinga.com
Via Benzinga · May 12, 2025
Breaking Down D-Wave Quantum: 8 Analysts Share Their Viewsbenzinga.com
Via Benzinga · May 12, 2025
JD: Seasonal Tailwinds Into Earnings?talkmarkets.com
With JD.com set to report earnings on May 13, you may not realize that the stock is also heading into one of its most statistically supportive seasonal windows.
Via Talk Markets · May 12, 2025
Can The US-China Tariff De-Escalation Send Bitcoin, Ethereum To New Highs?benzinga.com
The United States and China have agreed to a 90-day truce in their ongoing trade dispute, significantly scaling back reciprocal tariffs and establishing a structured negotiation fra
Via Benzinga · May 12, 2025